Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
08-10 October, 2025
Pharma MES 2025Pharma MES 2025
Not Confirmed
Not Confirmed
10-11 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
08-10 October, 2025
Pharma MES 2025Pharma MES 2025
Industry Trade Show
Not Confirmed
10-11 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
24 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascidian-therapeutics-appoints-dr-murray-a-abramson-as-chief-development-officer-and-establishes-ophthalmology-clinical-advisory-board-to-advance-acdn-01-for-treatment-of-stargardt-disease-302488604.html
19 Jun 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/roche-partners-with-ascidian-therapeutics-develop-gene-therapies-2024-06-18/
https://www.prnewswire.com/news-releases/ascidian-therapeutics-announces-first-ever-ind-for-an-rna-exon-editor-as-fda-approves-trial-plan-and-fast-tracks-acdn-01-in-stargardt-disease-and-other-abca4-retinopathies-302046287.html
Details:
ACDN-01 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stargardt Disease.
Lead Product(s): ACDN-01,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 21, 2024
Lead Product(s) : ACDN-01,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Details : ACDN-01 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stargardt Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2024
Details:
Ascidian will provide Roche exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets and will conduct discovery and preclinical activities.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: F. Hoffmann-La Roche
Deal Size: $1,842.0 million Upfront Cash: $42.0 million
Deal Type: Collaboration June 18, 2024
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $1,842.0 million
Deal Type : Collaboration
TECVAYLI® Biweekly Dosing Approved by U.S. FDA for Relapsed or Refractory Multiple Myeloma
Details : Ascidian will provide Roche exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets and will conduct discovery and preclinical activities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $42.0 million
June 18, 2024
Details:
ACDN-01 is the first-ever clinical-stage RNA exon editor, which is being evaluated in preclinical studies for the treatment of Stargardt disease & ABCA4 retinopathies.
Lead Product(s): ACDN-01,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 29, 2024
Lead Product(s) : ACDN-01,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascidian Receives FDA Approval for ACDN-01 Trial in Stargardt's and ABCA4 Retinopathies
Details : ACDN-01 is the first-ever clinical-stage RNA exon editor, which is being evaluated in preclinical studies for the treatment of Stargardt disease & ABCA4 retinopathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 29, 2024
Details:
The funds will be used to advance Ascidian's lead program, an RNA exon editor to halt the progression of Stargardt disease or other ABCA4 retinopathies, and additional programs in the company's pipeline.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Undisclosed
Sponsor: Apple Tree Partners
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 08, 2023
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Apple Tree Partners
Deal Size : $40.0 million
Deal Type : Series A Financing
Details : The funds will be used to advance Ascidian's lead program, an RNA exon editor to halt the progression of Stargardt disease or other ABCA4 retinopathies, and additional programs in the company's pipeline.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 08, 2023
ABOUT THIS PAGE